Keynote Financial Services LLC Acquires 141 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Keynote Financial Services LLC raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 12,577 shares of the biopharmaceutical company’s stock after buying an additional 141 shares during the period. Keynote Financial Services LLC’s holdings in Gilead Sciences were worth $1,054,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Manning & Napier Advisors LLC bought a new stake in Gilead Sciences during the second quarter worth about $25,328,000. Legal & General Group Plc grew its position in shares of Gilead Sciences by 0.8% in the 2nd quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock valued at $851,743,000 after acquiring an additional 93,068 shares during the period. IRON Financial LLC bought a new position in shares of Gilead Sciences in the 3rd quarter valued at about $830,000. GSA Capital Partners LLP acquired a new position in shares of Gilead Sciences during the 1st quarter worth about $462,000. Finally, Wealth Enhancement Advisory Services LLC raised its holdings in shares of Gilead Sciences by 13.1% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company’s stock valued at $19,630,000 after purchasing an additional 33,162 shares during the period. 83.67% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

GILD has been the subject of a number of research analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a report on Thursday. Robert W. Baird boosted their target price on Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a report on Thursday. Evercore ISI raised Gilead Sciences to a “strong-buy” rating in a report on Friday, August 9th. Leerink Partnrs upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 21st. Finally, Royal Bank of Canada raised their price objective on shares of Gilead Sciences from $75.00 to $81.00 and gave the stock a “sector perform” rating in a research report on Thursday. Eleven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $90.05.

Gilead Sciences Trading Up 6.8 %

GILD opened at $97.90 on Friday. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.32. The stock has a market capitalization of $121.88 billion, a price-to-earnings ratio of 119.39, a P/E/G ratio of 3.13 and a beta of 0.17. The company has a 50-day simple moving average of $84.58 and a 200 day simple moving average of $74.67.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The business had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same quarter last year, the business posted $2.29 EPS. The firm’s revenue for the quarter was up 7.0% on a year-over-year basis. Analysts predict that Gilead Sciences, Inc. will post 3.75 EPS for the current fiscal year.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 25,590 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the transaction, the insider now directly owns 99,599 shares in the company, valued at $9,113,308.50. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Gilead Sciences news, insider Merdad Parsey sold 25,590 shares of the stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the transaction, the insider now directly owns 99,599 shares in the company, valued at approximately $9,113,308.50. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Johanna Mercier sold 29,357 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the transaction, the insider now directly owns 78,127 shares of the company’s stock, valued at $6,545,480.06. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 62,437 shares of company stock valued at $5,374,825. 0.29% of the stock is currently owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.